BioMotiv

BioMotiv is a mission-driven pharmaceutical accelerator focused on advancing early-stage biomedical discoveries into medicines, primarily through in-licensing and collaborative development with academic institutions and corporate partners. It manages a diverse portfolio of preclinical therapeutic programs across cardiology, oncology, immunology, neurology, and rare diseases, with several programs advancing toward clinical evaluation. Major milestones include the out-licensing of a PAH portfolio to Chiesi Farmaceutici and co-founding Calida Therapeutics for monoclonal antibody development in thrombo-inflammatory disorders[1][2][5].